Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faricizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Faricizumab is a bispecific monoclonal antibody designed for the treatment of retinal vascular diseases. It is the first bispecific antibody approved for ophthalmic use, engineered to simultaneously bind and neutralize two distinct pathways: vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2). By inhibiting VEGF-A, faricizumab reduces vascular permeability and angiogenesis, while its inhibition of Ang-2 promotes vascular stability and desensitizes the blood vessels to the effects of VEGF-A. Developed by Roche and its subsidiary Genentech, faricizumab is administered via intravitreal injection. It is currently approved for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It is also under investigation for proliferative diabetic retinopathy and other retinal conditions.
- Brand names
- Vabysmo
- Other names
- faricizumab-svoa
02
Targets
ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on faricizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faricizumab.